The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
ctDNA analysis of NTRK fusion and mechanisms of acquired resistance to TRK inhibitors.
 
Karthigayini Sivaprakasam
No Relationships to Disclose
 
Guilherme Harada
Speakers' Bureau - AstraZeneca; Lilly; Merck; MSD; Pfizer
 
Noura J. Choudhury
Consulting or Advisory Role - G1 Therapeutics; Sanofi
Research Funding - Abbvie (Inst); Amgen (Inst); Harpoon therapeutics (Inst); Merck (Inst); Monte Rosa Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Royalties from Wolters Kluwer (Pocket Oncology).
 
Casey Savin
Employment - Loxo
 
Ronak H. Shah
Stock and Other Ownership Interests - 10X Genomics; AstraZeneca/MedImmune; Guardant Health; Regeneron; Roche
 
Michael F. Berger
Consulting or Advisory Role - AstraZeneca; Lilly; PetDx
Patents, Royalties, Other Intellectual Property - Provisional patent pending for "Systems and Methods for Detecting Cancer via cfDNA Screening"
 
Alexander E. Drilon
Stock and Other Ownership Interests - Treeline Biosciences
Honoraria - Answers in CME; Associazione Italiana Oncologia Toracica (AIOT); AstraZeneca; BeiGene; Chugai Pharma; Clinical Care Options/NCCN; Helsinn Therapeutics; i3 Health; IASLC; Ignyta/Genentech/Roche; Liberum; Loxo/Bayer/Lilly; Lung Cancer Research Foundation; Lungevity; NIH; OncLive/MJH Life Sciences; PER; Pfizer; Remedica; Remedica; Research to Practice; RV Mais; Sirio Libanes Hospital; TP Therapeutics; Verastem
Consulting or Advisory Role - 14ner Oncology/Elevation Oncology; Abbvie; Amgen; Applied Pharmaceutical Science; Archer; AstraZeneca; Axis Pharma; Bayer; BeiGene; BerGenBio; Blueprint Medicines; Clinical Care Options; Clinical Care Options; EMD Serono/Merck; Entos; EPG Health; Exelixis; Genentech/Roche; Hengrui Therapeutics; Ignyta; Janssen; Journal of the National Comprehensive Cancer Network; Liberum; Lilly; Loxo; Med Learning; Medscape; Melendi; Merus; Monopteros Therapeutics; Monte Rosa Therapeutics; MORE Health; Novartis; Nuvalent, Inc.; Ology Medical Education; Ology Medical Education; PeerView; Pfizer; Prelude Therapeutics; Repare Therapeutics; Takeda/Millennium; touchIME; Treeline Biosciences; Tyra Biosciences
Research Funding - Foundation Medicine
Patents, Royalties, Other Intellectual Property - Wolters Kluwer (Royalties for Pocket Oncology)
Other Relationship - Boehringer Ingelheim; GlaxoSmithKline; Merck; Merus; Pfizer; Pfizer; PharmaMar; Puma Biotechnology; Taiho Pharmaceutical; Teva